35 reports

  • PRESENTS THE GENETIC SYNDROMES AND THEIR RESPECTIVE GENETIC MUTATIONS THAT ARE ASSOCIATED WITH PANCREATIC CANCER RISK.
  • SELECTED GENETIC SYNDROMES WITH ASSOCIATED PANCREATIC CANCER RISK

Pancreatic Cancer: Opportunity Analysis and Forecast to 2026 Summary Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer, despite accounting for only 3% of new cancer diagnoses. Patients with advanced pancreatic cancer have a median...

  • Pancreatic Cancer
  • AbbVie Inc.
  • AstraZeneca PLC
  • Halozyme Therapeutics, Inc.
  • Merck & Co., Inc.
  • 3.4.5 DIAGNOSED INCIDENT CASES OF FAMILIAL PANCREATIC CANCER
  • 4.1 BIBLIOGRAPHY

K. et al. (2015) ' Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets', Nature Communications.

  • Pancreatic Cancer
  • Japan
  • United States
  • World
  • Forecast
  • PANCREATIC CANCER THERAPEUTICS, EFFICACY AND SAFETY RESULTS FOR KEY PARAMETERS - PIPELINE AND MARKETED PRODUCTS (LIGHT
  • PANCREATIC CANCER THERAPEUTICS, GLOBAL, DEVELOPMENTAL PIPELINE, PRECLINICAL 2015

Genetic Risk for Alcoholic Chronic Pancreatitis.

  • Pancreatic Cancer
  • World
  • Forecast
  • Market Size
  • Celgene Corporation

MGH is # ## in the Nation.

  • Artificial Intelligence
  • Healthcare
  • Hospital
  • Information Technology
  • Pancreatic Cancer

Pancreatic cancer

4546 5000 3864
  • HYPERACUTE-PANCREAS DRUG PROFILE
  • PRODUCT PROFILE (LATE STAGE): HYPERACUTE-PANCREAS

THERE ARE A RANGE OF INHERITED GENETIC SYNDROMES IMPLICATED IN INCREASED PANCREATIC CANCER RISK A number of inherited genetic syndromes and/ or gene mutations have been implicated in an increased risk of developing pancreatic cancer.

  • Pancreatic Cancer
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • NewLink Genetics Corporation
  • Taiho Pharmaceutical Co., Ltd.
  • VARIATION BY GEOGRAPHY/ETHNICITY

Table ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Discovery/Preclinical Trial Details

The drug candidate is developed based on Genetically Modified Fly technology.

  • Oncology
  • Pancreatic Cancer
  • United States
  • World
  • AstraZeneca PLC

WHIM is a genetic primary immunodeficiency disease caused by the abberant trafficking of specific immune cells that are critical for proper immune system functions.

  • Pancreatic Cancer
  • Renal Cancer
  • United States
  • Product Initiative
  • BioLineRx Ltd.

In theory, Ampligen induced crossprotection may extend to any vaccine for viruses subject to a high mutation rate and genetic drift.

  • Pancreatic Cancer
  • Therapy
  • Vaccine
  • Canada
  • Hemispherx Biopharma, Inc.

Each ADS represents the right to receive one ordinary share.

  • Pancreatic Cancer
  • Europe
  • United States
  • Company
  • Erytech Pharma SA
  • OCT 24, 2016: PHARMACYTE BIOTECH SELECTS DR. MANUEL HIDALGO AS PRINCIPAL INVESTIGATOR FOR ITS PANCREATIC CANCER CLINICAL TRIAL
  • NOV 01, 2016: PHARMACYTE BIOTECH REQUESTS PRE-IND MEETING WITH FDA FOR ITS PANCREATIC CANCER CLINICAL TRIAL

Efforts to identify the genetic code for the responsible enzyme in these cell lines are underway.

  • Marijuana
  • Pancreatic Cancer
  • United States
  • Company
  • PharmaCyte Biotech, Inc.
  • 14.7 PHARMACYTE BIOTECH INC. 14.7.1 Key Facts

FIGURE ##.

  • Pancreatic Cancer
  • World
  • Forecast
  • Market Size
  • PharmaCyte Biotech, Inc.
  • PANCREATIC CANCER - PIPELINE BY ACLARIS THERAPEUTICS INC
  • PANCREATIC CANCER - PIPELINE BY APOSENSE LTD

Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018 Summary Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas, a large gland situated in the abdominal cavity that is responsible for the secretion of digestive fluids and insulin. Signs...

  • Pancreatic Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • ITALY PANCREATIC CANCER THERAPEUTICS & DIAGNOSTICS MARKET,
  • 6.3 BY GEOGRAPHY

One such case is the use of Ipilimumab.

  • Chemotherapy
  • Pancreatic Cancer
  • United States
  • World
  • Market Size

In theory, Ampligen induced crossprotection may extend to any vaccine for viruses subject to a high mutation rate and genetic drift.

  • Biopharmaceutical
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • Hemispherx Biopharma, Inc.
  • DIAGNOSTIC BIOMARKER - PANCREATIC CANCER - PRODUCT DESCRIPTION
  • DIAGNOSTIC BIOMARKER - PANCREATIC CANCER - PRODUCT STATUS

CLINICAL GENETIC TEST VOLUME(##) GREW ##% DRIVEN BY THE INCLUSION OF CLARIENT' S RESULTS IN THE CONSOLIDATED TOTAL.

  • Cancer
  • Clinical Trial
  • Pancreatic Cancer
  • United States
  • Proteome Sciences

In theory, Ampligen induced cross-protection may extend to any vaccine for viruses subject to a high mutation rate and genetic drift.

  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • Supply
  • BioPharma company
  • MAR 26, 2018: PRECLINICAL DATA SHOWING SYNERGY OF BIOTHERA PHARMACEUTICALS' IMPRIME PGG AND A CD40 AGONIST IN A PANCREATIC CANCER MODEL PRESENTED AT KEYSTONE SYMPOSIA
  • 5. All the trials included are unique trials.

The lengthy amount of time it has taken to complete these tests is because PharmaCyte is using genetically modified live human cells as part of its combination product that utilizes the Cell-in-a-Box® technology plus low dose ifosfamide as a novel therapy to treat LAPC.

  • Drug Discovery And Development
  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • World

ADALTA LTD Ambrx Inc (Ambrx) is a biopharmaceutical company which focuses on the discovery and development of proteinbased medicines by using its expanded genetic code.

  • Cancer
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • BioLineRx Ltd.

ARQ ## is being dosed in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR## genetic alterations as part of the phase ## portion of a biomarker driven phase ##/ ## trial.

  • Drug Discovery And Development
  • Hepatitis
  • Pancreatic Cancer
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Lung Cancer
  • Pancreatic Cancer
  • World
  • Product Initiative
  • Eli Lilly & Co.

## Alzheimer' s Disease ## Amyotrophic Lateral Sclerosis ## Chronic Renal Failure ## Coronary Artery Disease ## Depression ## Diabetic Retinopathy ## Duchenne Muscular Dystrophy ## Heart Failure ## Liver Fibrosis ##

  • Cancer
  • Mental Health
  • Pancreatic Cancer
  • Pathology
  • SomaLogic, Inc.

NA : Not Available Source: Global Markets Direct harbor a specific genetic lesion in the gene Neurofibromatosis Type ## (NF##), which results in the loss of the protein Merlin and increased sensitivity to FAK inhibition.

  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative
  • Verastem, Inc.

In June 2006, Insmed Incorporated Limited has withdrawn orphan drug designation for mecasermin rinfabate for the treatment of growth hormone deficiency and primary insulin-like growth factor-## deficiency due to molecular or genetic defects.

  • Cancer
  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative

University of Utah undertakes research on animal subjects, radiation and laboratory safety, resource for genetic and epidemiologic research, and others.

  • Pancreatic Cancer
  • Therapy
  • Japan
  • Company
  • NanoCarrier Co., Ltd.
  • NECUPARANIB - DRUG PROFILE
  • CELLULAR IMMUNOTHERAPY TO TARGET GM-CSFR FOR PANCREATIC CANCER - DRUG PROFILE

The clinical responses have been independent of high-risk clinical or genetic features.

  • Chemotherapy
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative
  • Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Featured News & Press Releases

M## extended survival of a genetically engineered mouse model for pancreatic cancer when it was combined with the current standard of care chemotherapy gemcitabine.

  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative
  • Progen Pharmaceuticals Limited
  • COURTAGEN LIFE SCIENCES, INC. PIPELINE PRODUCTS SUMMARY BY DEVELOPMENT STAGE DEVELOPMENTAL STAGE

" There are a large number of patients who suffer from non-genetic forms of epilepsy or seizures, or may not need a genetic diagnosis, but who are being treated with anticonvulsants.

  • Breast Cancer
  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Courtagen Life Sciences, Inc.
  • DORMANT PROJECTS (CONTD..4), H2 2016

## deficiency due to molecular or genetic defects from EU Community register.

  • Chemotherapy
  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative

Sickle cell disease is one of the most prevalent genetic disorders in the U. S.

  • Pancreatic Cancer
  • Therapy
  • United States
  • World
  • Product Initiative